2015
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, Dhodapkar KM. Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo. The Journal Of Immunology 2015, 194: 950-959. PMID: 25539810, PMCID: PMC4380504, DOI: 10.4049/jimmunol.1401686.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntigens, SurfaceAntineoplastic Combined Chemotherapy ProtocolsCTLA-4 AntigenCytokinesGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunophenotypingIpilimumabLymphocytes, Tumor-InfiltratingNeoplasmsNivolumabProgrammed Cell Death 1 ReceptorSignal TransductionT-Lymphocyte SubsetsConceptsPD-1T cellsCTLA-4Checkpoint blockadeCombination therapyReceptor occupancyCombination immune checkpoint blockadeCTLA-4 immune checkpointsPD-1 receptor occupancyTransitional memory T cellsAnti-PD-1 therapyAnti CTLA-4Immune-based combinationsPD-1 blockadeSoluble IL-2RImmune checkpoint blockadeNK cell functionMemory T cellsTherapy-induced changesT cell activationTumor T cellsHuman T cellsRemarkable antitumor effectImmunologic changesImmunologic effects
2012
Integrated analysis of tumor samples sheds light on tumor heterogeneity.
Parisi F, Micsinai M, Strino F, Ariyan S, Narayan D, Bacchiocchi A, Cheng E, Xu F, Li P, Kluger H, Halaban R, Kluger Y. Integrated analysis of tumor samples sheds light on tumor heterogeneity. The Yale Journal Of Biology And Medicine 2012, 85: 347-61. PMID: 23012583, PMCID: PMC3447199.Peer-Reviewed Original ResearchMeSH KeywordsCell Line, TumorChromosome MappingChromosomes, HumanDNA Copy Number VariationsEvolution, MolecularGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, NeoplasmHumansIntercellular Signaling Peptides and ProteinsKaryotypingMelanomaMutationOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotideProto-Oncogene Proteins B-rafConceptsHigh-throughput profilingGene expression levelsExpression levelsDifferent gene expression levelsGene expression profilingCopy number analysisExpression profilingSNP arrayPathway analysisCopy number statusWnt pathwayTumor samplesNumber alteration profilesTumor heterogeneityTumor evolutionCopy number alteration profilesGenomic aberrationsIntegrated analysisCell linesTumor subclonesNumber analysisNumber statusProfilingDriver mutationsRecurrent association
2011
Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF. Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma. Molecular Cancer Research 2011, 9: 801-812. PMID: 21521745, PMCID: PMC3117976, DOI: 10.1158/1541-7786.mcr-10-0512.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisCell Line, TumorCell MovementCell ProliferationErbB ReceptorsGene Expression Regulation, NeoplasticGene Knockdown TechniquesHEK293 CellsHumansInfant, NewbornMelanocytesMelanomaPhosphoproteinsPhosphorylationProteomicsReceptor Protein-Tyrosine KinasesReceptor, IGF Type 2RNA, Small InterferingSignal TransductionSkin NeoplasmsSTAT3 Transcription FactorConceptsTherapeutic targetReceptor tyrosine kinasesMelanoma cellsPotential therapeutic targetIdentifies potential therapeutic targetsActive receptor tyrosine kinasesTyrosine kinaseMelanoma cell migrationReceptor expressionBreast cancerAxl knockdownAutocrine circuitTherapeutic interventionsCancer subtypesReceptor tyrosine kinase activationTyrosine kinase activationNovel targetActivated receptorsAxlRNA knockdownMelanomaCell migrationHER3KnockdownIGF1R
2009
Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications
Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, Sznol M, Ariyan S, Narayan D, Bacchiocchi A, Molinaro A, Kluger Y, Deng M, Tran N, Zhang W, Picardo M, Enghild JJ. Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications. PLOS ONE 2009, 4: e4563. PMID: 19234609, PMCID: PMC2642998, DOI: 10.1371/journal.pone.0004563.Peer-Reviewed Original ResearchMeSH KeywordsApoptosisAzacitidineBiomarkers, TumorCell Line, TumorCell ProliferationComputational BiologyDecitabineDNA DamageDrug Resistance, NeoplasmEpigenesis, GeneticGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMelanomaConceptsDNA damage responseMelanoma cell responseDamage responseGene expressionIntegrative analysisDifferential gene expressionMelanoma cell strainsGene expression profilesDNA promoter methylationP53-independent mannerHistone modificationsImproved combination therapiesEpigenetic modifiersTGFbeta pathwayBioinformatics analysisProtein stabilityEpigenetic modulationResistant melanoma cellsExpression profilesGrowth arrestPromoter methylationCancer cellsCell strainsProteasome inhibitorsPTEN mutations
2006
Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma
McCarthy MM, DiVito KA, Sznol M, Kovacs D, Halaban R, Berger AJ, Flaherty KT, Camp RL, Lazova R, Rimm DL, Kluger HM. Expression of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptors 1 and 2 in Melanoma. Clinical Cancer Research 2006, 12: 3856-3863. PMID: 16778114, PMCID: PMC1839847, DOI: 10.1158/1078-0432.ccr-06-0190.Peer-Reviewed Original ResearchMeSH KeywordsGene Expression RegulationGene Expression Regulation, NeoplasticHumansMelanomaNeoplasm MetastasisOligonucleotide Array Sequence AnalysisReceptors, TNF-Related Apoptosis-Inducing LigandReceptors, Tumor Necrosis FactorReference Values
2004
Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas
Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, Lin A, Kluger HM, Berger AJ, Cheng E, Trombetta ES, Wu T, Niinobe M, Yoshikawa K, Hannigan GE, Halaban R. Expression Profiling Reveals Novel Pathways in the Transformation of Melanocytes to Melanomas. Cancer Research 2004, 64: 5270-5282. PMID: 15289333, DOI: 10.1158/0008-5472.can-04-0731.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCell Transformation, NeoplasticCohort StudiesDown-RegulationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMelanocytesMelanomaMiceNuclear ProteinsOligonucleotide Array Sequence AnalysisPrognosisSignal TransductionSkin NeoplasmsSurvival RateTranscription FactorsTransfectionTwist-Related Protein 1Ubiquitin ThiolesteraseConceptsGlobal differential gene expressionMembrane trafficking eventsNovel pathwayNormal melanocytesHelix protein TwistAdditional transcriptional regulatorsDifferential gene expressionMelanoma cellsTransformation of melanocytesCpG promoter methylationNormal human melanocytesTrafficking eventsTranscriptional regulatorsEmbryonic developmentGrowth suppressorChromosomal regionsExpression profilingGene expressionNotch pathwayOligonucleotide microarraysMelanoma tissue microarrayDifferential expressionGenesHuman melanocytesGrowth advantageHer2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study
Kluger HM, DiVito K, Berger AJ, Halaban R, Ariyan S, Camp RL, Rimm DL. Her2/neu is not a commonly expressed therapeutic target in melanoma – a large cohort tissue microarray study. Melanoma Research 2004, 14: 207-210. PMID: 15179190, DOI: 10.1097/01.cmr.0000130874.33504.2f.Peer-Reviewed Original ResearchMeSH KeywordsCohort StudiesFemaleGene Expression Regulation, NeoplasticHumansImmunohistochemistryMaleMelanomaNeoplasm StagingOligonucleotide Array Sequence AnalysisReceptor, ErbB-2ConceptsHER2/neu expressionHER2/neuNeu expressionMelanoma specimensNeu stainingMelanoma patientsLarge cohortPositive HER2/neu expressionChemotherapy-resistant malignancyPrimary cutaneous lesionNumerous new agentsTissue microarray studyMonoclonal antibody trastuzumabAdjuvant therapyCutaneous specimensTrastuzumab therapyMetastatic lesionsBreslow depthClark levelClinicopathological dataCutaneous lesionsPrimary lesionTumor stageMetastatic melanomaBreast cancer
2002
COMMENTARY Pigmentation in Melanomas: Changes Manifesting Underlying Oncogenic and Metabolic Activities
Halaban R. COMMENTARY Pigmentation in Melanomas: Changes Manifesting Underlying Oncogenic and Metabolic Activities. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2002, 13: 3-8. PMID: 12201672, DOI: 10.3727/096504002108747908.Peer-Reviewed Original ResearchMeSH KeywordsGene Expression Regulation, NeoplasticHumansMelanomaMonophenol MonooxygenaseSkin NeoplasmsSkin PigmentationConceptsMelanocyte-specific gene expressionTranscription factor MITFDownregulation of tyrosinaseEpigenetic levelV-ATPaseRate-limiting enzymeTranscriptional activityGene expressionAcidified microenvironmentsAmelanotic melanoma cellsC-MycActivity of tyrosinaseEnhanced glycolysisMelanin synthesisExtracellular acidificationMelanoma tumorsTYR activityMelanoma cellsMetabolic activityPigmentationAnaerobic conditionsTyrosinase activityMetastatic melanocytic lesionsMetabolic changesTyrosinase
1996
Growth factors and melanomas.
Halaban R. Growth factors and melanomas. Seminars In Oncology 1996, 23: 673-81. PMID: 8970586.Peer-Reviewed Original ResearchMeSH KeywordsCarrier ProteinsCell Cycle ProteinsCell Transformation, NeoplasticCyclin-Dependent Kinase Inhibitor p16Cyclin-Dependent KinasesEndothelinsFibroblast Growth Factor 2Gene Expression Regulation, NeoplasticGrowth SubstancesHumansMelanocytesMelanomaReceptors, Growth FactorSignal TransductionConceptsCyclin-dependent kinasesFibroblast growth factorNormal human melanocytesMast/stem cell growth factorCell cycleCDK inhibitor p16INK4Human melanocytesMelanoma cellsGrowth factorHepatocyte growth factor/scatter factorStem cell growth factorGrowth factor/scatter factorSynergistic growth factorsNeuropeptide endothelin-1Cell cycle progressionPhosphorylation of retinoblastomaGrowth constraintsWild-type p53Unregulated expressionTranscriptional activityNegative regulatorCycle progressionResult of inactivationBasic fibroblast growth factorInhibitory complex
1992
Growth Factors, Receptor Kinases, and Protein Tyro sine Phosphatases in Normal and Malignant Melanocytes
Halaban R, Fan B, Ahn J, Funasaka Y, Gitay-Goren H, Neufeld G. Growth Factors, Receptor Kinases, and Protein Tyro sine Phosphatases in Normal and Malignant Melanocytes. Journal Of Immunotherapy 1992, 12: 154-161. PMID: 1445804, DOI: 10.1097/00002371-199210000-00002.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsGene Expression Regulation, NeoplasticGrowth SubstancesHumansMelanocytesMelanomaProtein-Tyrosine KinasesReceptors, Fibroblast Growth FactorConceptsMast cell growth factorReceptor tyrosine kinasesFibroblast growth factorTyrosine kinaseTyrosyl-phosphorylated proteinsExpression of pigmentationTransmembrane receptor tyrosine kinaseHepatocyte growth factorGrowth factorGrowth factor/receptor systemsHuman melanocyte proliferationBasic FGFMelanoma cellsProtein tyrosineReceptor kinasePigment cellsBasic fibroblast growth factorFGF receptorsKinaseHuman melanoma cellsNormal melanocytesKIT kinaseMalignant phenotypeMelanocyte proliferationCell growth factor